Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06926595 · ClinicalTrials.gov registry record · Phase 2
Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
A Phase 2 study, sponsored by Milton S. Hershey Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT06926595 is a Phase 2 study that is actively recruiting participants, run by Milton S. Hershey Medical Center. The registered enrollment target is 41 participants.
The verdict
NCT06926595, a Phase 2 study, is actively recruiting participants, sponsored by Milton S. Hershey Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophylaxis of Graft-versus-Host Disease (GVHD) in patients undergoing allogeneic stem cell transplantation following reduced-intensity or non-myeloablative conditioning. The study will focus on matched sibling, matched unrelated, and haploidentical peripheral blood stem cell donors. The primary endpoint is 1-year GVHD-Free Relapse-Free Survival (GRFS). The study seeks to determine if low-dose PTCy offers similar outcomes as higher doses, with potentially reduced toxicity.
Interventions
- DRUG Cyclophosphamide (primary intervention for GVHD prophylaxis)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2031-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06926595
The ClinicalTrials.gov registry entry for NCT06926595 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cyclophosphamide (primary intervention for GVHD prophylaxis) is the first listed.
NCT06926595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06926595 about?
NCT06926595 is a clinical study titled "Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention". This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophylaxis of Graft-versus-Host Disease (GVHD) in patients undergoing allogeneic stem cell transplantation following reduced-intensity or non-myeloa...
What is the current status of trial NCT06926595?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2026-03-09. Estimated completion is 2031-11-01.
What interventions are being tested in trial NCT06926595?
The interventions under investigation include: Cyclophosphamide (primary intervention for GVHD prophylaxis) (DRUG).
Who is sponsoring clinical trial NCT06926595?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.